Table 2.
Adverse events during follow-up.
| Adverse event | Treatment group (n = 90) | Control group (n = 90) | P |
|---|---|---|---|
| Overall prevalence | 51(56.7) | 47(52.2) | 0.549 |
| Fatigue | 4(4.4) | 2(2.2) | 0.678 |
| Fever | 3(3.3) | 2(2.2) | 1 |
| Diarrhea | 7(7.8) | 5(5.6) | 0.55 |
| Abdominal pain | 9(10.0) | 11(12.2) | 0.635 |
| Dyspepsia | 10(11.1) | 8(8.9) | 0.619 |
| Nausea | 6(6.7) | 9(10.0) | 0.418 |
| Abnormal CBC | 12(13.3) | 10(11.1) | 0.649 |
| Serious adverse event | 0(0) | 0(0) | - |
| Any other complains | 18(20.0) | 13(14.4) | 0.324 |
Note: values in parentheses are percentages. Abnormal CBC was defined as one or more than one of complete blood counts (CBC) were abnormal. Any other complains include cough, headache, itching, dizziness, arthralgia, etc.